Importers Notice of Application - 2008
FR Doc E8-18045[Federal Register: August 6, 2008 (Volume 73, Number 152)] [Notices] [Page 45780-45781] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr06au08-85]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on March 26, 2008, BA Research International LLC, 10550 Rockley Road, Suite 150, Houston, Texas 77099- 0000, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II:
|4-Methylaminorex (cis isomer) (1590)||I|
|Gamma Hydroxybutyric Acid (2010)||I|
|Lysergic acid diethylamide (7315)||I|
|4-Methyl-2,5-dimethoxyamphet- amine (7395)||I|
|3,4-Methylenedioxymethamphet- amine (7405)||I|
|Etorphine (except HCL) (9056)||I|
|Alphacetylmethadol except levo-alphacetylmethadol (9603)||I|
|Etorphine HCL (9059)||II|
|Dextropropoxyphene, bulk (non-dosage forms) (9273)||II|
|Opium, raw (9600)||II|
|Opium, powdered (9639)||II|
The company plans to import analytical reference standards for analytical testing of blood samples from clinical trials.
Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be filed no later than September 5, 2008.
This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: July 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E8-18045 Filed 8-5-08; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).